ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Budapest, Budapest, HUN:

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Active, not recruiting
Multiple Myeloma
Drug: Venetoclax
Drug: Carfilzomib

Phase 2

AbbVie
AbbVie

Budapest, Hungary and 31 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Budapest, Hungary and 218 other locations

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: Bortezomib

Phase 3

AbbVie
AbbVie

Budapest, Hungary and 72 other locations

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participant...

Active, not recruiting
Multiple Myeloma
Drug: Belantamab mafodotin
Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Budapest, Hungary and 140 other locations

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Budapest, Hungary and 135 other locations

the efficacy and safety of BMS-986393 versus standard regimens in adult participants with Relapsed or Refractory and Lanalidomide-refractory Multiple...

Begins enrollment in 3 months
Relapsed or Refractory Multiple Myeloma (RRMM)
Drug: Daratumumab
Drug: Dexamethasone

Phase 3

Juno Therapeutics

Budapest, Hungary and 100 other locations

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Mezigdomide
Drug: Dexamethasone

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Budapest, Hungary and 206 other locations

the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple...

Enrolling
Multiple Myeloma
Plasma Cell Disorder
Drug: HDP-101

Phase 1, Phase 2

Heidelberg Pharma

Budapest, Hungary and 15 other locations

subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Budapest, Hungary and 163 other locations

A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and saf...

Active, not recruiting
Multiple Myeloma
Drug: Placebo +G-CSF
Drug: BL-8040 1.25 mg/kg + G-CSF

Phase 3

BioLineRx

Budapest, Hungary and 17 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems